WO2007038453A3 - Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation - Google Patents
Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation Download PDFInfo
- Publication number
- WO2007038453A3 WO2007038453A3 PCT/US2006/037332 US2006037332W WO2007038453A3 WO 2007038453 A3 WO2007038453 A3 WO 2007038453A3 US 2006037332 W US2006037332 W US 2006037332W WO 2007038453 A3 WO2007038453 A3 WO 2007038453A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vegf
- agent
- growth factor
- vascular endothelial
- endothelial growth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Use of an anti-vascular endothelial growth factor (VEGF) agent for the manufacture of a medicament to ameliorate inflammation at a site in the body that may be the eye, a joint, the brain, etc. or to reduce corneal neovascularization. In one embodiment, one or more other agents, such as non-steroidal anti-inflammatory agents, steroids, etc., may be included with the anti-VEGF agent. The anti-VEGF agent may be bevacizumab, ranibizumab, sunitinib maleate, pegaptanib, etc.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/234,970 | 2005-09-26 | ||
US11/234,970 US20070071754A1 (en) | 2005-09-26 | 2005-09-26 | Method to ameliorate inflammation |
US11/348,017 | 2006-02-06 | ||
US11/348,017 US20070071756A1 (en) | 2005-09-26 | 2006-02-06 | Delivery of an agent to ameliorate inflammation |
US11/348,465 | 2006-02-06 | ||
US11/348,465 US20070072933A1 (en) | 2005-09-26 | 2006-02-06 | Delivery of an ocular agent |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007038453A2 WO2007038453A2 (en) | 2007-04-05 |
WO2007038453A3 true WO2007038453A3 (en) | 2007-11-29 |
Family
ID=37806769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/037332 WO2007038453A2 (en) | 2005-09-26 | 2006-09-26 | Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007038453A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8905963B2 (en) | 2010-08-05 | 2014-12-09 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US9417238B2 (en) | 2009-01-29 | 2016-08-16 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US9474756B2 (en) | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
US9492315B2 (en) | 2010-08-05 | 2016-11-15 | Forsight Vision4, Inc. | Implantable therapeutic device |
US9526654B2 (en) | 2013-03-28 | 2016-12-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8435510B2 (en) | 2007-08-08 | 2013-05-07 | Sutter West Bay Hospitals | Platelet derived growth factor receptor supports cytomegalovirus infectivity |
DE102007038730A1 (en) * | 2007-08-16 | 2009-02-19 | Carl Zeiss Meditec Ag | Evidence of Human Vascular Endothelial Growth Factor |
EP2666510B1 (en) † | 2007-12-20 | 2017-10-18 | University Of Southern California | Apparatus for controlled delivery of therapeutic agents |
BRPI0908502A2 (en) * | 2008-02-21 | 2017-05-23 | Ista Pharmaceuticals | ophthalmic aines as adjuvants |
EP2379109B1 (en) * | 2008-12-16 | 2020-10-07 | Bausch Health Companies Inc. | Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
JP2012524058A (en) * | 2009-04-15 | 2012-10-11 | フォンダツィオーネ アイアールシーシーエス イスティトゥト ナツィオナーレ デイ トゥモリ | Use of multikinase inhibitors in the treatment of hypervascular permeability |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
WO2012019139A1 (en) | 2010-08-05 | 2012-02-09 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
CA2818612C (en) | 2010-11-19 | 2020-12-29 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
EP4249059A3 (en) | 2011-06-28 | 2023-11-29 | ForSight Vision4, Inc. | An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye |
SI2755600T1 (en) | 2011-09-16 | 2021-08-31 | Forsight Vision4, Inc. | Fluid exchange apparatus |
US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
US9636299B2 (en) * | 2012-03-29 | 2017-05-02 | Xavier University Of Louisiana | Method for treating diabetic retinopathy |
EP2858628A1 (en) * | 2012-06-25 | 2015-04-15 | Bayer HealthCare LLC | Topical ophthalmological pharmaceutical composition containing sunitinib |
US8747852B1 (en) | 2012-12-28 | 2014-06-10 | Randal Tanh Hoang Pham | Methods of treating pterygium |
AU2014236455B2 (en) | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
MX2016000385A (en) * | 2013-07-11 | 2016-04-29 | Novartis Ag | Use of a vegf antagonist in treating retinopathy of prematurity. |
US10258503B2 (en) | 2014-07-15 | 2019-04-16 | Forsight Vision4, Inc. | Ocular implant delivery device and method |
US10500091B2 (en) | 2014-11-10 | 2019-12-10 | Forsight Vision4, Inc. | Expandable drug delivery devices and methods of use |
WO2016200688A1 (en) | 2015-06-06 | 2016-12-15 | Cloudbreak Therapeutics, Llc | Compositions and methods for treating pterygium |
TWI700085B (en) | 2015-06-22 | 2020-08-01 | 新源生物科技股份有限公司 | Use of ophthalmic formulations of tyrosine kinase inhibitors |
CN108430405B (en) | 2015-11-20 | 2021-04-13 | 弗赛特影像4股份有限公司 | Porous structures for sustained release drug delivery devices |
US11617680B2 (en) | 2016-04-05 | 2023-04-04 | Forsight Vision4, Inc. | Implantable ocular drug delivery devices |
WO2017210130A1 (en) | 2016-06-02 | 2017-12-07 | Cloudbreak Therapeutics, Llc | Compositions and methods of using nintedanib for improving glaucoma surgery success |
WO2019103906A1 (en) | 2017-11-21 | 2019-05-31 | Forsight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999013909A1 (en) * | 1997-09-12 | 1999-03-25 | Toagosei Co., Ltd. | Corneal neovascularization inhibitors |
US20050058688A1 (en) * | 2003-02-22 | 2005-03-17 | Lars Boerger | Device for the treatment and prevention of disease, and methods related thereto |
WO2005074942A1 (en) * | 2004-02-04 | 2005-08-18 | Retmed Pty Ltd | Slow release steroid composition |
US20050192429A1 (en) * | 2001-04-13 | 2005-09-01 | Rosen Craig A. | Vascular endothelial growth factor 2 |
WO2005084188A2 (en) * | 2004-02-25 | 2005-09-15 | Massachusetts Eye & Ear Infirmary | Systemic inflammatory markers and age-related macular degeneration (amd) |
WO2005110362A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Biodegradable ocular implants with long-term release characteristics |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
WO2006088650A2 (en) * | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
WO2007011873A2 (en) * | 2005-07-15 | 2007-01-25 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
WO2007047626A1 (en) * | 2005-10-14 | 2007-04-26 | Alcon, Inc. | Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis |
-
2006
- 2006-09-26 WO PCT/US2006/037332 patent/WO2007038453A2/en active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999013909A1 (en) * | 1997-09-12 | 1999-03-25 | Toagosei Co., Ltd. | Corneal neovascularization inhibitors |
US20050192429A1 (en) * | 2001-04-13 | 2005-09-01 | Rosen Craig A. | Vascular endothelial growth factor 2 |
US20050058688A1 (en) * | 2003-02-22 | 2005-03-17 | Lars Boerger | Device for the treatment and prevention of disease, and methods related thereto |
WO2005074942A1 (en) * | 2004-02-04 | 2005-08-18 | Retmed Pty Ltd | Slow release steroid composition |
WO2005084188A2 (en) * | 2004-02-25 | 2005-09-15 | Massachusetts Eye & Ear Infirmary | Systemic inflammatory markers and age-related macular degeneration (amd) |
WO2005110362A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Biodegradable ocular implants with long-term release characteristics |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
WO2006088650A2 (en) * | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
WO2007011873A2 (en) * | 2005-07-15 | 2007-01-25 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
WO2007047626A1 (en) * | 2005-10-14 | 2007-04-26 | Alcon, Inc. | Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis |
Non-Patent Citations (8)
Title |
---|
AMANO SHIRO ET AL: "Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization", IOVS, vol. 39, no. 1, January 1998 (1998-01-01), pages 18 - 22, XP008079338 * |
BEER P M ET AL: "VITREOUS LEVELS OF UNBOUND BEVACIZUMAB AND UNBOUND VASCULAR ENDOTHELIAL GROWTH FACTOR IN TWO PATIENTS", RETINA, PHILADELPHIA, PA, US, vol. 26, no. 8, 2006, pages 871 - 876, XP008079356, ISSN: 0275-004X * |
DATABASE WPI Week 19, 25 March 1999 Derwent World Patents Index; Class 991, Page 9, AN 1999-229406, XP002437620, KAWAKAMI Y. ET AL.: "Corneal neovascularisation inhibitors" * |
KANTOFF PHILIP: "RECENT PROGRESS IN MANAGEMENT OF ADVANCED PROSTATE CANCER", ONCOLOGY, PRR, HUNTINGTON, NY, US, vol. 19, no. 5, April 2005 (2005-04-01), pages 631 - 636, XP008079352, ISSN: 0890-9091 * |
MICHELS STEPHAN ET AL: "Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.", OPHTHALMOLOGY JUN 2005, vol. 112, no. 6, June 2005 (2005-06-01), pages 1035 - 1047, XP005825968, ISSN: 1549-4713 * |
ROSENFELD PHILIP J ET AL: "OPTICAL COHERENCE TOMOGRAPHY FINDINGS AFTER AN INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) FOR MACULAR EDEMA FROM CENTRAL RETINAL VEIN OCCLUSION", OPHTHALMIC SURGERY, LASERS AND IMAGING, SLACK, INC., THOROFARE, NJ, US, vol. 36, no. 4, July 2005 (2005-07-01) - August 2005 (2005-08-01), pages 336 - 339, XP008079763, ISSN: 1542-8877 * |
ROSENFELD PHILIP J ET AL: "OPTICAL COHERENCE TOMOGRAPHY FINDINGS AFTER AN INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION", OPHTHALMIC SURGERY, LASERS AND IMAGING, SLACK, INC., THOROFARE, NJ, US, vol. 36, no. 4, 22 June 2005 (2005-06-22), pages 331 - 335, XP008079762, ISSN: 1542-8877 * |
SUGITA S: "Intravitreal anti-inflammatory treatment for uveitis", BRITISH JOURNAL OF OPHTHALMOLOGY 2007 UNITED KINGDOM, vol. 91, no. 2, 2007, pages 135 - 136, XP008079353, ISSN: 0007-1161 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9417238B2 (en) | 2009-01-29 | 2016-08-16 | Forsight Vision4, Inc. | Posterior segment drug delivery |
US8905963B2 (en) | 2010-08-05 | 2014-12-09 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US9033911B2 (en) | 2010-08-05 | 2015-05-19 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
US9492315B2 (en) | 2010-08-05 | 2016-11-15 | Forsight Vision4, Inc. | Implantable therapeutic device |
US9526654B2 (en) | 2013-03-28 | 2016-12-27 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
US9474756B2 (en) | 2014-08-08 | 2016-10-25 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2007038453A2 (en) | 2007-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007038453A3 (en) | Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation | |
WO2012037410A3 (en) | Estrogen receptor modulators and uses thereof | |
WO2007047607A3 (en) | Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues | |
EP2056818A4 (en) | Compositions and methods for neuroprotection | |
WO2010147957A3 (en) | Dithiol compounds, derivatives, and uses therefor | |
WO2015187596A3 (en) | Antibody-drug conjugates, their preparation and their therapeutic use | |
WO2010141648A3 (en) | Artificial tears and therapeutic uses | |
WO2011151079A3 (en) | Preparation for use in ophthalmology and retinal surgery | |
DK1833799T3 (en) | 3-Phenyl-pyrazole derivatives as modulators of 5-HT-2α-serotonin receptor useful for the treatment of diseases related thereto | |
WO2010136492A3 (en) | Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye. | |
EP2346520A4 (en) | Curcuminoids and its metabolites for the application in ocular diseases | |
EP1807391A4 (en) | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases | |
WO2009089260A3 (en) | Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases | |
WO2006060618A3 (en) | Topical nepafenac formulations | |
SG10201907588XA (en) | Androgen Receptor Modulators And Uses Thereof | |
WO2006042329A3 (en) | Crig polypeptide for prevention and treatment of complement-associated disorders | |
WO2007130824A3 (en) | Fused heterocylic compounds and their use as mglur5 modulators | |
EP2424360A4 (en) | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases | |
CL2010001406A1 (en) | Ophthalmic pharmaceutical composition comprising povidone iodine, and a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, an antibacterial, an anti-allergic or an anti-glaucoma compound; and method to preserve the composition. | |
WO2012047525A3 (en) | Folate conjugates for treating inflammation of the eye | |
WO2006095029A3 (en) | Di-polymer protein conjugates and processes for their preparation | |
DK2319517T3 (en) | APPLICATION OF PRODRUGS TO OCULAR, INTRAVENOUS ADMINISTRATION | |
IL182424A0 (en) | Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases | |
NZ605022A (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
WO2007130825A3 (en) | Fused heterocyclic compounds and their use as mglur5 modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06815379 Country of ref document: EP Kind code of ref document: A2 |